Fontolizumab

Fontolizumab ^?

Monoclonal antibody
Type	Whole antibody
Source	Humanized (from mouse)
Target	interferon gamma
Clinical data
Legal status	?
Identifiers
CAS number	326859-36-3 N
ATC code	None
UNII	6J92H2439Z Y
KEGG	D04242 Y
Chemical data
Formula	?
Mol. mass	ca. 150 kDa
N (what is this?)  (verify)

Fontolizumab (planned trade name HuZAF) is a humanized monoclonal antibody^[1] and an immunosuppressive drug for the treatment of auto-immune diseases like Crohn's disease.^[2] A phase II clinical trial investigating the use for rheumatoid arthritis was terminated because the first phase did not meet the endpoint.^[3]

References

1. ↑ Statement On A Nonproprietary Name Adopted By The Usan Council - Fontolizumab, American Medical Association.
2. ↑ Reinisch, W; De Villiers, W; Bene, L; Simon, L; Rácz, I; Katz, S; Altorjay, I; Feagan, B et al. (2009). "Fontolizumab in moderate to severe Crohn's disease: A phase 2, randomized, double-blind, placebo-controlled, multiple-dose study". Inflammatory bowel diseases 16 (2): NA. doi:10.1002/ibd.21038. PMID 19637334.  |displayauthors= suggested (help)
3. ↑ ClinicalTrials.gov NCT00281294 A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis